SALARIUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5 USD | -1.46% |
|
-0.20% | -23.08% |
| Mar. 25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
| Mar. 25 | Top Premarket Gainers | MT |
Presenter SpeechDavid Arthur (Executives)Good evening, everyone. Let's go ahead and find a sea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening and further optimization with structure-activity relationship studies.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.5
USD
Average target price
3.25
USD
Spread / Average Target
+550.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.08% | 2.16M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Transcript : Salarius Pharmaceuticals, Inc. Presents at 16th Annual Noble Conference Emerging Growth Investor Conference, Feb-17-2020 05
